Get the Stockscreener App
0.4772
0.67%
-0.0032
After Hours:
.49
0.0128
+2.68%
Heron Therapeutics Inc stock is traded at $0.4772, with a volume of 1.53M.
It is down -0.67% in the last 24 hours and up +14.30% over the past month.
Heron Therapeutics Inc is a commercial-stage biotechnology company. The company is focused on improving the lives of patients by developing treatments and commercializing therapeutic solutions to address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
See More
Previous Close:
$0.4804
Open:
$0.4881
24h Volume:
1.53M
Relative Volume:
0.46
Market Cap:
$90.32M
Revenue:
$150.71M
Net Income/Loss:
$-30.94M
P/E Ratio:
-2.7006
EPS:
-0.1767
Net Cash Flow:
$-20.86M
1W Performance:
+11.00%
1M Performance:
+14.30%
6M Performance:
-67.32%
1Y Performance:
-75.15%
1-Day Range:
$0.4605
$0.4918
1-Week Range:
$0.4108
$0.4999
52-Week Range:
$0.382
$1.98
Heron Therapeutics Inc Stock (HRTX) Company Profile
Name
Heron Therapeutics Inc
Sector
Industry
Phone
(858) 251-4400
Address
4242 CAMPUS POINT COURT, SUITE 200, SAN DIEGO, CA
Compare HRTX vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HRTX
Heron Therapeutics Inc
|
0.4772 | 90.93M | 150.71M | -30.94M | -20.86M | -0.1767 |
VRTX
Vertex Pharmaceuticals Inc
|
482.00 | 121.95B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
675.19 | 70.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
874.74 | 52.94B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
183.29 | 38.35B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
271.37 | 36.40B | 4.29B | 577.22M | 641.34M | 4.2086 |
Heron Therapeutics Inc Stock (HRTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-03-26 | Downgrade | Needham | Buy → Hold |
| Jun-09-25 | Initiated | H.C. Wainwright | Buy |
| Jun-13-24 | Initiated | Rodman & Renshaw | Buy |
| Apr-23-24 | Initiated | CapitalOne | Overweight |
| Mar-13-24 | Reiterated | Needham | Buy |
| May-27-20 | Initiated | Guggenheim | Buy |
| Feb-20-20 | Reiterated | Needham | Buy |
| Jan-16-19 | Reiterated | Needham | Buy |
| Apr-05-18 | Initiated | Evercore ISI | Outperform |
| Mar-19-18 | Reiterated | Mizuho | Buy |
| Mar-01-18 | Reiterated | Needham | Buy |
| Jan-03-18 | Initiated | Leerink Partners | Outperform |
| Sep-27-17 | Initiated | Northland Capital | Outperform |
| Feb-27-17 | Initiated | Needham | Buy |
| Oct-26-16 | Initiated | Aegis Capital | Buy |
| Sep-06-16 | Resumed | Lake Street | Buy |
| May-03-16 | Initiated | Cantor Fitzgerald | Buy |
| Dec-10-15 | Initiated | Lake Street | Buy |
| Sep-23-15 | Reiterated | Leerink Partners | Outperform |
| Sep-02-15 | Initiated | BofA/Merrill | Buy |
| Aug-03-15 | Reiterated | Brean Capital | Buy |
| Jun-30-15 | Reiterated | JMP Securities | Mkt Outperform |
| Jun-19-15 | Reiterated | Leerink Partners | Outperform |
| Aug-07-14 | Initiated | Noble Financial | Buy |
View All
Heron Therapeutics Inc Stock (HRTX) Latest News
Heron Therapeutics Inc (HRTX) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
RANI Stock Price and Chart — NASDAQ:RANI - TradingView
Heron Therapeutics, Inc. (NASDAQ:HRTX) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Heron Therapeutics (HRTX) Stock Sees Fair Value Cut After Cinvanti Patent Decision - Yahoo Finance
HRTX Stock Price, Quote & Chart - ChartMill
Heron Therapeutics updates investors on business progress as development pipeline remains the key va - Ad-hoc-news.de
HRTXHeron Therapeutics Inc Options - Finviz
Is Heron Therapeutics, Inc. (HRTX) Stock a Recovery Opportunity After Cinvanti Patent Court Ruling? - Insider Monkey
Heron Therapeutics Inc (HRTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Heron Therapeutics Faces Nasdaq Minimum Bid Price Deficiency - The Globe and Mail
Heron Therapeutics Receives Nasdaq Minimum Bid Price Notification - Moomoo
Heron Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Forbes William P - Moomoo
Heron Therapeutics Inc Actuals & Estimates (NASDAQ:HRTX) - TradingView
Heron Therapeutics, Inc. 8-K Filing: Nasdaq Listing Status, Company Details & Key SEC Disclosures (June 25, 2026) - Minichart
Heron Therapeutics Inc Actuals & Estimates (BX:AXD2) - TradingView
Heron Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Nasdaq warns Heron Therapeutics (NASDAQ: HRTX) on sub-$1.00 bid price - Stock Titan
Enterprise value to EBITDA forward of Heron Therapeutics, Inc. – NASDAQ:HRTX - TradingView
Enterprise value to EBIT forward of Heron Therapeutics, Inc. – NASDAQ:HRTX - TradingView
Price to sales forward of Heron Therapeutics, Inc. – NASDAQ:HRTX - TradingView
Enterprise value to revenue forward of Heron Therapeutics, Inc. – NASDAQ:HRTX - TradingView
HRTX Forecast — Price Target — Prediction for 2027 - TradingView
HRTX Q1 2026 Earnings: EPS Misses Estimates Sharply as Losses Widen, Shares Decline 2.33%Pre-Announcement Alert - dars.gov.et
Heron Therapeutics (HRTX) Edges Higher: Testing Key Resistance After Recent GainsRisk Reversal - Bölüm Sonu Canavarı
Heron Therapeutics Stocklong-term strategy under pressure after reverse split and Nasdaq warning - AD HOC NEWS
Heron Therapeutics (HRTX) Surges 7.8%: Testing Key Resistance at $0.44Advance Decline Volume - dars.gov.et
Heron Therapeutics Inc (HRTX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Heron Therapeutics Inc (HRTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Heron Therapeutics Inc (HRTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Heron Therapeutics Inc (HRTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Heron Therapeutics (NASDAQ: HRTX) CFO exercises RSUs and withholds shares for taxes - Stock Titan
Heron Therapeutics stockholders approve director slate and plan amendments at annual meeting - Investing.com India
Heron Therapeutics Inc (HRTX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Heron Therapeutics Inc (HRTX) Institutional Confidence - TradingKey
Heron Therapeutics Inc (HRTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Heron Therapeutics Inc (HRTX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Heron Therapeutics stockholders approve director slate and plan amendments at annual meeting By Investing.com - Investing.com South Africa
Heron Therapeutics (HRTX) holders approve board, equity share increases and tax plan - Stock Titan
HRTX: All director nominees and proposals were approved, with no questions from stockholders - TradingView
HRTX Q1 2026 Earnings: Deep EPS Miss Triggers 10.7% Stock DeclineGuidance Accuracy Score - newsline.com
Heron Therapeutics In A Tough Spot After Cinvanti Court Loss (Rating Downgrade) - Seeking Alpha
Heron Therapeutics (HRTX) EVP converts 12,500 RSUs into common shares - Stock Titan
H.C. Wainwright Maintains Heron Therapeutics(HRTX.US) With Buy Rating, Maintains Target Price $2 - Moomoo
TANG KEVIN C's Strategic Acquisition in Aurinia Pharmaceuticals Inc - GuruFocus
HRTX Maintains Buy Rating -- Price Target Lowered to $2.00 by HC Wainwright - GuruFocus
Heron Therapeutics Appeals Ruling Invalidating CINVANTI Patents - The Globe and Mail
H.C. Wainwright Maintains Heron Therapeutics(HRTX.US) With Buy Rating, Cuts Target Price to $2 - Moomoo
HRTX Downgraded by Needham -- Outlook Adjusted to Hold - GuruFocus
Heron Therapeutics to Appeal Delaware Court Ruling Invalidating CINVANTI® Patents - Minichart
Why Did FULC, MVIS, HRTX Stocks Plunge To 52-Week Lows Today? - Stocktwits
CINVANTI patent claims invalidated as Heron Therapeutics (NASDAQ: HRTX) plans appeal - Stock Titan
Heron Therapeutics Inc Stock (HRTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.50%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):